CME Breakfast Symposium: Updates in Hepatocellular Carcinoma: Clinical Decision-making Among an Array of New Options

Moderator: Ghassan Abou-Alfa, MD
Supported by an educational grants from Eisai, Inc and Merck & Co., Inc.
7:30 am – 7:40 am
Introduction and Pretest
7:40 am – 8:00 am
Advances in Targeted Therapies and Checkpoint Inhibitors for HCC
8:00 am – 8:20 am
Clinical Case Presentations
8:20 am – 8:30 am
Posttest and Question and Answer

Welcome

8:30 am – 8:35 am
Opening Remarks

Head and Neck Cancer

Moderator: Edward S. Kim, MD, FACP
8:35 am – 8:38 am
Pretest
8:39 am – 8:59 am
Current Treatment of Recurrent/Metastatic Disease
Robert I. Haddad, MD
9:00 am – 9:20 am
Locally Advanced Head and Neck Cancer
Joshua M. Bauml, MD
9:21 am – 9:41 am
HPV Strategies
Robert L. Ferris, MD, PhD
9:42 am – 10:02 am
Combination Immuno-oncology and Future Approaches
Nabil F. Saba, MD, FACP
10:03 am – 10:25 am
Discussion and Posttest

Exhibit Hall Break

10:25 am – 10:55 am
Refreshments and Networking

Genitourinary Cancer

Moderator: Sanjiv S. Agarwala, MD
10:55 am – 10:58 am
Pretest
10:59 am – 11:19 am
Castration-resistant Prostate Cancer: Current Approach
Ravi A. Madan, MD
11:20 am – 11:40 am
Newly Diagnosed Metastatic Renal Cell Carcinoma: Immunotherapy or Targeted Therapy?
Petros Grivas, MD, PhD
11:41 am – 12:01 pm
Bladder Cancer: Is Immunotherapy the New Standard?
Petros Grivas, MD, PhD
12:02 pm – 12:22 pm
Rising PSA: When to Pull the Trigger?
Ravi A. Madan, MD
12:23 pm – 12:45 pm
Discussion and Posttest
12:45 pm – 12:50 pm
Break

CME Lunch Symposium: Applying Checkpoint Inhibitors in NSCLC and SCLC: A Symposium at HEMONC Today New York

Moderator: Edward S. Kim, MD, FACP
Supported by an educational grant from Merck & Co., Inc.
12:50 pm – 1:00 pm
Introduction and Pretest
1:00 pm – 1:20 pm
Checkpoint Inhibitors in NSCLC: Insight into Timing, Sequencing, and Combination Treatment
1:20 pm – 1:40 pm
Checkpoint Inhibitors in Small Cell Lung Cancer – Clinical Implications of the Latest Findings
1:40 pm – 1:50 pm
Posttest and Question and Answer
1:50 pm – 1:55 pm
Break

Hematologic Malignancies: Immunotherapies for Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma and Acute Lymphocytic Leukemia

Moderator: David L. Porter, MD
1:55 pm – 1:58 pm
Pretest
1:59 pm – 2:19 pm
CAR T Cells for Hematologic Malignancy: Why All the Excitement?
  • CAR T Introduction: Mechanism of Action
  • FDA Approved Indications and Products
  • Expected Outcomes and Potentially New Indications
David L. Porter, MD
2:20 pm – 2:40 pm
CARs: Out of the Showroom and into the Clinic
  • Summary CAR T for NHL
  • Determine Which Patients are Suitable Candidates for CAR T Therapy
  • Benefits, Risks and Costs of CAR-T Cell Therapy
  • Best Practices for Referring Those Patients to a Center that is Accredited to Administer CAR T
Nirav N. Shah, MD, MSHP
2:41 pm – 3:01 pm
Treating Relapsed NHL: So Many Choices
  • Focus on Non-traditional Chemotherapy
  • CAR T vs. Autologous Stem Cell Transplant
  • Immunotherapy
  • Biological Therapies
Michael R. Bishop, MD
3:02 pm – 3:22 pm
CLL: An End to Traditional Chemotherapy?
Danielle M. Brander, MD
3:23 pm – 3:43 pm
AML: Progress. Finally?
  • Discussion of New FDA Approved Therapies, including CD33 Antibodies, FLT Inhibitors and IDH Inhibitors
Alexander Perl, MD
3:44 pm – 3:55 pm
Discussion and Posttest

Exhibit Hall Break

3:55 pm – 4:25 pm
Refreshments and Networking in the Exhibit Hall

Case Studies in Head and Neck Cancers, Genitourinary Cancer and Hematologic Malignancies

Moderators: Sanjiv S. Agarwala, MD; Edward S. Kim, MD, FACP; David L. Porter, MD
4:25 pm – 4:28 pm
Pretest
4:29 pm – 4:44 pm
Head and Neck Cancer Case
Joshua M. Bauml, MD
4:44 pm – 4:49 pm
Question & Answer
4:50 pm – 5:05 pm
Genitourinary Cancer Case
Ravi A. Madan, MD
5:05 pm – 5:10 pm
Question & Answer
5:11pm – 5:26 pm
Hematologic Malignancies Case
First Therapy for CLL: Choosing Wisely
Danielle M. Brander, MD
5:26 pm – 5:31 pm
Question & Answer
5:31 pm – 5:35 pm
Posttest